mesowatch
HomeHormone Levels in Blood Could Indicate Mesothelioma Risk
divider

Study Uncovers Link Between Hormone Levels and Pleural Mesothelioma

Blood Test Results In A Medical Lab

For individuals exposed to asbestos, the looming threat of malignant pleural mesothelioma remains a serious concern. A recent study, however, suggests that a simple blood test measuring hormone levels could potentially identify those most at risk, paving the way for earlier intervention.

Hormones as Cancer Biomarkers

Conducted by researchers from various Italian centers, the study investigated the potential of certain steroid hormones as biomarkers for predicting mesothelioma risk. Previous research has linked the hormone estrogen (17-β-estradiol) to mesothelioma development.

Using advanced analytical techniques, the researchers examined 20 steroid hormones in serum samples from three groups:

  • 67 mesothelioma patients
  • 39 healthy individuals with asbestos exposure
  • 35 unexposed healthy controls

A Three-Hormone Signature Emerges

“We identified a signature of three hormones—estradiol, DHEA-S, and androstenedione—that showed a distinct pattern differentiating asbestos-exposed individuals from those not exposed,” explained lead author Barbara Nuvoli.

The study revealed:

  • Elevated estradiol levels in both mesothelioma patients and asbestos-exposed individuals
  • Increased DHEA-S levels in the asbestos-exposed group
  • Decreased androstenedione levels in the asbestos-exposed group

When combined into a biomarker scoring system, this three-hormone signature effectively distinguished between the study groups. Mesothelioma patients also exhibited this high-risk hormone pattern.

An Early Warning Signal

Interestingly, estradiol levels did not significantly differ between early and late-stage mesothelioma, highlighting this marker’s potential for early detection in high-risk populations.

“If validated, this simple hormone panel from a blood test could identify asbestos-exposed individuals at the highest risk for mesothelioma, allowing us to monitor them more closely and ideally intervene earlier before the cancer advances,” said study co-author Dr. Roberta Libener.

Potential Treatment Implications

The study also discovered that elevated levels of the enzymes 5α-reductase 1 and 17β-hydroxysteroid dehydrogenase 2, involved in estradiol metabolism, correlated with worse and better overall mesothelioma prognosis, respectively. This finding hints at the potential for hormone-targeted treatment approaches.

While larger studies are necessary, this novel hormone biomarker signature represents a promising advancement toward improving mesothelioma screening and early diagnosis—a critical need given the cancer’s aggressive nature when detected late.

Jean Brannum

Reading Time: 1 mins

Published On: May 27, 2024

Jean Brannum - author

Jean Brannum is a science writer who enjoys researching and discussing disease and cancer treatments. She recently graduated from NC State with a degree in biology and a focus in science journalism.

More to Read

Section Divider

Amna Anees - November 17, 2024

CHMP Recommends Pembrolizumab and Chemo for Pleural Mesothelioma

Mini Divider
Mesowatch Logo

Mesowatch serves as an industry watchdog and advocates for patients and families affected by asbestos by providing reliable and up-to-date news stories and information on asbestos and mesothelioma.

NAVIGATE

About UsEditorial GuidelinesNewsSupport and ResourcesPrivacy PolicySitemap

CONTACT US

Email: support@mesowatch.com

Phone: (866) 402-1000

Address: 3260 N Hayden Rd, Suite 210, Scottsdale, AZ 85251

Copyright © 2024 by Mesowatch. All Rights Reserved.
At Mesowatch, we strive to provide helpful information for your journey. Please remember that the content on our website is for informational purposes only and is protected by copyright law. It is not a substitute for professional medical or legal advice. We encourage you to consult qualified professionals for any health or legal concerns. Disclaimer